Versión de HTML Básico
85
Andrés Salgado-Miranda
Exacerbación inmunohistológica de la queratoconjuntivitis vernal
tis. Curr Opin Allergy Clin Immunol. 2012; 12(5):534 – 539.
7. Ono SJ, Abelson MB. Allergic conjunctivitis: Update on pathophy-
siology and prospects for future treatment. J Allergy Clinc Immunol 2005;
115(1):118 – 122.
8. Chigbu D. The pathophysiology of ocular allergy: a review. Con-
tact Lens Anterior Eye. 2009; 32:3-15.
9. Leonardi A, Bogacka E, Fauquert J.L, et al. Ocular allergy: recogni-
zing and diagnosing hypersensitivity disorders of the ocular surface. Aller-
gy 2012; 67:1327-1337.
10. Leonardi Am Busca Motterle L, Cavarzeran, et al. Case series of
406 vernal keratoconjunctivitis patients: a demographic and epidemiolo-
gical study. Acta Opthalmol Scand. 2006; 84: 406 – 410.
11. Uchio E, Itoh Y, Kadonosono K. Topical Bromfenac Sodium for
long the managment of vernal keratoconjunctivitis. Ophtahlmologica
2007; 221:153 – 158.
12. Lee Y, Woong S, Yul KK. Application for tacrolimus ointment in
treating refractory inflammatory ocular surface diseases. Am J Ophthal-
mology. 2013; 155(5): 804 – 813.
13. Rikkers S, Holland G, Drayton G. Topical tacrólimus treatment
of atopic eyelid disease. Am J Ophthalmology. 2003; 135(3):297 – 302.
14. Joseph M, Kaufman H, Insler M. Topical tacrólimus ointment for
treatment of refractory anterior segment inflammatory disorders. Cor-
nea. 2005; 24:417 – 420.
15. Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, et
al. Vernal keratoconjunctivitis: Result a novel therapy with 0.1% topical
ophthalmic FK-506 ointment. J Allergy Clinc Immunolo. 2004; 113 (2):
355- 358.
16. Attas-Fox l, Barkana Y, Iskhakov V, et al. Topical tacrólimus 0.03%
ointment for intractable allergic conjunctivitis: an open – label pilot study.
Curr Eye Res. 2008; 33(7): 545 – 549.
17. Kino T, Hatanaka H, Miyata S, et al. FK 506, a novel immuno-
suppressant isolated from Streptomyces. II. Immunosuppressive effect of
FK506 in vitro. J Antibiotic. 1987; 40: 1256 – 1265.
18. Miyazaki D, Tominaga T, Nagata Y, et al. Therapeutic effects of
tacrólimus ointment for refractory ocular surface inflammatory diseases.
2008; 115 (6): 988 – 992.
19. Kheirkhah A, Zavareh MK, Farzbod F, et al. Topical 0,005% tacró-
limus eye drop for refractory vernal keratoconjunctivitis. Eye. 2011; 25:
872 – 880.
20. Pleyer U, Lutz S, Jusco W, et al. Ocular absorption of topically
applied FK506, from liposomal and oil formulations in the rabbit eye. In-
vest Ophthalmol Vis Sci. 1993; 34: 2737 – 2742.
21. Whitcup S, Pleyer U, Lai J, et al. Topical liposome – encapsula-
ted FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol
Inflamm. 1998; 6:51-56.
22. Shoji J, Inada N, Sawa M. Evaluation of novel scoring system
named 5-5-5 exacerbation grading scale for allergic conjunctivitis disease.
Allergol Int. 2009;58(4):591-597.
23. Ramirez R, Reina Z, et al. Queratoconjuntivitis vernal
refractaria:¿es el tacrólimus una opción terapéutica? Estudio prospectivo.
Aler Asma Inmunol Pediatr. 2012; 21(1): 5-12.
24. Leonardi A, Lazzarini D, Motterle L, et al. Vernal keratoconjuncti-
vitis – like disease in adults. Am J Ophthalmol. 2013; 155(5):768-803.
25. Sherif Z, Pleyer U. Corticoids in Ophthalmology: Past – Present –
Future,Ophthalmologica; Sep/Oct 2002; 216: 305-315.
26. Carnaha M, Goldstein D, Ocular complications of topical, peri-
ocular, and systemic corticosteroids. Curren Opin Ophth. 2000; 11(6): 478
– 483.
27. Kymionis G, Goldman D, Ide T, et al. Tacrolimus ointment 0,03%
in the eye for the treatment of giant papillary conjunctivitis. Cornea.
2008; 27: 228-229
28. Kymionis G, Kankariya V, Kontadakis. Tacrolimus ointment 0,03%
for treatment of refractory childhood phlyctenular keratoconjunctivitis.
Corneal 2012; 31: 950 – 952.
29. Thaci D, Salgo R. Malignancy concerns of topical calcineurin
inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol.
2010; 28: 52 – 56.
30. Martinez S, Redondo J. Inhibitors of the calcioneurin/NFAT
pathway. Curr Med Chem 2004; 11: 997 – 1007.
31. Goodman & Gilman´s. The pharmacological basis of therapeu-
tics.McGraw Hill. Philadelphia. 2011.
32. Palomares P, Del Amo V, Moratal B, et al. Ciclosporina tópica
como alternativa eficaz en el tratamiento de las queratitis intersticiales
herpéticas. Arch Soc Esp Oftalmol, 2010; 85 (2):81 – 82.
33. Bonini S, Sacchetti M, Mantelli F, et al. Clinical grading of vernal
keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007; 7:436 – 441.